These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 8766548)

  • 1. Semi-allogeneic (F1) versus fully allogeneic blood transfusions: differences in their ability to induce specific immunological unresponsiveness.
    Roelen DL; Dover EL; Niimi M; Young NT; Morris PJ; Wood KJ
    Eur J Immunol; 1996 Jul; 26(7):1468-74. PubMed ID: 8766548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of indefinite survival of fully allogeneic cardiac grafts and generation of regulatory cells by intratracheal delivery of alloantigens under blockade of the CD40 pathway.
    Uchida N; Shirasugi N; Akiyama Y; Matsumoto K; Shimazu M; Kitajima M; Hamano K; Aramaki O; Ikeda Y; Niimi M
    Transplantation; 2003 Mar; 75(6):878-84. PubMed ID: 12660518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in non-MHC alloantigens promote tissue rejection but fail to mediate allogeneic co-operation and autoimmunity in mice neonatally injected with semi-allogeneic F1 B cells.
    Ramos A; Merino R; Merino J
    Immunology; 1994 Jun; 82(2):287-93. PubMed ID: 7927500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term immunologic tolerance induction in chimeric mice after bone marrow transplantation across major histocompatibility barriers: persistent or redeveloping immunologic responsiveness after prolonged survival.
    Sugiura K; Yasumizu R; Iwai H; Inaba MM; Toki J; Ogura M; Hara I; Good RA; Ikehara S
    Thymus; 1991 Nov; 18(3):137-53. PubMed ID: 1838450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft persistence effectively induces and maintains donor-specific unresponsiveness.
    Nishinaka H; Nakafusa Y; Hirano T; Takeda K; Kawano R; Nakano M; Arima T; Nakamura K; Kamei T; Tanaka M
    J Surg Res; 1997 Mar; 68(2):145-52. PubMed ID: 9184673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responsiveness against allogeneic platelet transfusions is determined by the recipient's major histocompatibility complex class II phenotype.
    Sayeh E; Aslam R; Speck ER; Le-Tien H; Lazarus AH; Freedman J; Semple JW
    Transfusion; 2004 Nov; 44(11):1572-8. PubMed ID: 15504162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged survival of rat hepatic allografts pretreated with a single donor-specific blood transfusion: the distribution of donor cells expressing class I major histocompatibility complex antigens in the recipient.
    Yamaguchi Y; Goto M; Makino Y; Kikuchi N; Hamaguchi H; Hisama N; Miyanari N; Mori K; Ogawa M
    J Surg Res; 1996 Feb; 61(1):23-9. PubMed ID: 8769937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor bone marrow cells play a role in the prevention of accelerated graft rejection induced by semi-allogeneic spleen cells in transplantation.
    de Moraes LV; Bueno V; Marguti I; Martins GA; Vallochi AL; Yamamoto GL; Panajotopoulos N; Mengel JO; Rizzo LV
    Transpl Immunol; 2008 Feb; 18(4):330-7. PubMed ID: 18158119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of portal venous tolerant long-term MHC Class I L(d)-specific skin graft survival in transgenic 2CF1 mice.
    Margenthaler JA; Landeros K; Kataoka M; Flye MW
    Transpl Immunol; 2003; 11(1):23-9. PubMed ID: 12727472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of operational tolerance by random blood transfusion combined with anti-CD4 antibody therapy. A protocol with significant clinical potential.
    Bushell A; Morris PJ; Wood KJ
    Transplantation; 1994 Jul; 58(2):133-9. PubMed ID: 8042231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential susceptibility of cytotoxic and helper T cell precursors to neonatal tolerization to histocompatibility antigens.
    Ishizaka ST; Carnaud C; Stutman O
    J Immunol; 1986 Oct; 137(7):2093-9. PubMed ID: 2944947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmunity following neonatal tolerance to alloantigens: role of donor I-A and I-E molecules.
    Kramar G; Schurmans S; Berney M; Izui S; del Giudice G; Lambert PH
    J Autoimmun; 1995 Apr; 8(2):177-92. PubMed ID: 7612147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological unresponsiveness induced by recipient cells transfected with donor MHC genes.
    Madsen JC; Superina RA; Wood KJ; Morris PJ
    Nature; 1988 Mar; 332(6160):161-4. PubMed ID: 3279318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between lymphocyte-induced donor-specific tolerance and donor cell recirculation. Role of class I and class II major histocompatibility complex.
    Sheng-Tanner XF; Miller RG
    Transplantation; 1994 Apr; 57(7):1081-7. PubMed ID: 8165707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bidirectional blockade of CD4 and major histocompatibility complex class II molecules: an effective immunosuppressive treatment in the mouse heart transplantation model.
    Ito H; Hamano K; Fukumoto T; Wood KJ; Esato K
    J Heart Lung Transplant; 1998 May; 17(5):460-9. PubMed ID: 9628564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen presentation by Langerhans cells in vivo: donor-derived Ia+ Langerhans cells are required for induction of delayed-type hypersensitivity but not for cytotoxic T lymphocyte responses to alloantigens.
    Peeler JS; Niederkorn JY
    J Immunol; 1986 Jun; 136(12):4362-71. PubMed ID: 3519767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of intrathymic inoculation of soluble antigens in the induction of specific unresponsiveness to rat islet allografts without transient recipient immunosuppression.
    Oluwole SF; Jin MX; Chowdhury NC; Ohajekwe OA
    Transplantation; 1994 Nov; 58(10):1077-81. PubMed ID: 7974714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.